Cargando…

The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?

Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to normal care after resolution of Covid-19 symptoms. Due to the sudden onset of the pandemic,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czupryniak, Leszek, Dicker, Dror, Lehmann, Roger, Prázný, Martin, Schernthaner, Guntram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485772/ https://www.ncbi.nlm.nih.gov/pubmed/34598700 http://dx.doi.org/10.1186/s12933-021-01389-1

Ejemplares similares

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
por: Schernthaner, Guntram, et al.
Publicado: (2019)

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010
por: Schernthaner, Guntram, et al.
Publicado: (2011)

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
por: Schernthaner, Guntram, et al.
Publicado: (2019)

Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
por: Schernthaner, Guntram
Publicado: (2021)

Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
por: Janež, Andrej, et al.
Publicado: (2020)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
por: Schernthaner, Guntram
Publicado: (2021)

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
por: Schernthaner, Guntram, et al.
Publicado: (2018)

Management of hyperglycemia in type 2 diabetes: evidence and uncertainty
por: Esposito, Katherine, et al.
Publicado: (2013)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Fetuin-A Levels Are Increased in Patients With Type 2 Diabetes and Peripheral Arterial Disease
por: Lorant, David Peter, et al.
Publicado: (2011)

Renal Function but Not Asymmetric Dimethylarginine Is Independently Associated with Retinopathy in Type 2 Diabetes
por: Krzyzanowska, Katarzyna, et al.
Publicado: (2011)

Priority setting for the introduction of rotavirus vaccine: what evidence was essential?
por: Glass, Roger I.
Publicado: (2018)

What was Glaucoma Called Before the 20th Century?
por: Leffler, Christopher T., et al.
Publicado: (2015)

Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time
por: Hörtenhuber, Thomas, et al.
Publicado: (2013)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
por: Evans, Marc
Publicado: (2018)

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)
por: Saely, Christoph H., et al.
Publicado: (2023)

Type 1 diabetes: what is the role of autoimmunity in β cell death?
por: Donath, Marc Y.
Publicado: (2022)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

Risk factors for cancer development in type 2 diabetes: A retrospective case-control study
por: Dąbrowski, Mariusz, et al.
Publicado: (2016)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study
por: Dąbrowski, Mariusz, et al.
Publicado: (2017)

Responding to COVID19: What is happening for our vulnerable children and young people?
por: Lehmann, Jennifer
Publicado: (2020)

To B or Not to B: (Anti)bodies of Evidence on the Crime Scene of Type 1 Diabetes?
por: Mallone, Roberto, et al.
Publicado: (2011)

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?
por: Popovic, Djordje S., et al.
Publicado: (2021)

Radiological weapons: what type of threat?
por: Mapstone, James, et al.
Publicado: (2005)

Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery
por: Herz, Carsten T., et al.
Publicado: (2021)

Slope of change in HbA(1c) from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2018)

Breakthrough COVID-19 Infections: What Are They and What Do They Look Like?
por: Elicker, Brett M.
Publicado: (2022)

Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
por: Home, Philip, et al.
Publicado: (2014)

Neural Networks, Cognition, and Diabetes: What Is the Connection?
por: Jones, David T.
Publicado: (2012)

β-cell dedifferentiation in diabetes is important, but what is it?
por: Weir, Gordon C, et al.
Publicado: (2013)

What procalcitonin brings to management of sepsis in the ICU
por: Wolff, Michel, et al.
Publicado: (2010)

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
por: Usui, Ryota, et al.
Publicado: (2019)

Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC()
por: Bloomgarden, Zachary, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hppmrgjrag546pg6mfb58vndo5